HUMULIN 3070 INJECTION 100 iuml

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

INSULIN ISOPHANE (HUMAN); SOLUBLE INSULIN (HUMAN)

Available from:

ELI LILLY (SINGAPORE) PTE LTD

ATC code:

A10AD01

Dosage:

70.00%

Pharmaceutical form:

INJECTION

Composition:

INSULIN ISOPHANE (HUMAN) 70%; SOLUBLE INSULIN (HUMAN) 30%

Administration route:

SUBCUTANEOUS, INTRAMUSCULAR

Prescription type:

Pharmacy Only

Manufactured by:

Eli Lilly and Company (Primary Packager)

Authorization status:

ACTIVE

Authorization date:

1991-06-03

Patient Information leaflet

HUMULIN
®
 R
(Regular human insulin [recombinant DNA origin], Lilly)
HUMULIN
®
 N
(NPH human insulin [recombinant DNA origin], Lilly)
Isophane suspension
HUMULIN
®
 L
(Lente human insulin [recombinant DNA origin], Lilly)
Zinc Suspension
HUMULIN
®
 30/70
30% Regular insulin human injection USP [recombinant DNA origin])
and
(70% NPH insulin human isophane suspension [recombinant DNA origin]
DESCRIPTION
HUMULIN  R:  A  sterile,  clear  colorless,  aqueous  solution  of  human  insulin 
(DNA)  adjusted  to  a  pH  of  7.0  to  7.8.  Contains  m-Cresol  0.25%  added  during 
manufacture as a preservative.
HUMULIN N: A sterile suspension of a white, crystalline precipitate of isophane human 
insulin (DNA) in an isotonic phosphate buffer adjusted to a pH of 6.9 to 7.5. Contains 
m-Cresol 0.16% and phenol 0.065% added during manufacture as a preservative.
HUMULIN  L:  A  sterile  suspension  of  30%  amorphous  and  70%  crystalline 
human  insulin  (DNA)  zinc  suspension,  adjusted  to  a  pH  of  6.9  to  7.5.  Contains 
methylparaben 0.1% added during manufacture as a preservative.
HUMULIN  30/70:  A  sterile  suspension  of  human  insulin  in  the  proportion  of  
30%  soluble  insulin  and  70%  isophane  insulin.  Contains  m-Cresol  0.16%  and 
phenol 0.065% added during manufacture as a preservative.
All presentations are available in strengths of 100 units per ml. Not all presentations 
are available in the respective markets.
INDICATIONS
For  the  treatments  of  patients  with  diabetes  mellitus  for  whom  diet  and/or  oral 
agents are not sufficient.
The use of human insulin (DNA) may be of particular benefit in the treatment of 
the following: insulin allergy, insulin-induced lipodystrophy, insulin�

Summary of Product characteristics

HUMULIN
® R
(Regular human insulin [recombinant DNA origin], Lilly)
HUMULIN
® N
(NPH human insulin [recombinant DNA origin], Lilly)
Isophane suspension
HUMULIN
® L
(Lente human insulin [recombinant DNA origin], Lilly)
Zinc Suspension
HUMULIN
® 30/70
30% Regular insulin human injection USP [recombinant DNA origin])
and
(70% NPH insulin human isophane suspension [recombinant DNA origin]
DESCRIPTION
HUMULIN
R:
A
sterile,
clear
colorless,
aqueous
solution
of
human
insulin
(DNA) adjusted to a pH of 7.0 to 7.8. Contains m-Cresol 0.25% added
during
manufacture as a preservative.
HUMULIN N: A sterile suspension of a white, crystalline precipitate of
isophane human
insulin (DNA) in an isotonic phosphate buffer adjusted to a pH of 6.9
to 7.5. Contains
m-Cresol 0.16% and phenol 0.065% added during manufacture as a
preservative.
HUMULIN L: A sterile suspension of 30% amorphous and 70% crystalline
human insulin (DNA) zinc suspension, adjusted to a pH of 6.9 to 7.5.
Contains
methylparaben 0.1% added during manufacture as a preservative.
HUMULIN 30/70: A sterile suspension of human insulin in the proportion
of
30% soluble insulin and 70% isophane insulin. Contains m-Cresol 0.16%
and
phenol 0.065% added during manufacture as a preservative.
All presentations are available in strengths of 100 units per ml. Not
all presentations
are available in the respective markets.
INDICATIONS
For the treatments of patients with diabetes mellitus for whom diet
and/or oral
agents are not sufficient.
The use of human insulin (DNA) may be of particular benefit in the
treatment of
the following: insulin allergy, insulin-induced lipodystrophy, insulin
resistance, and
labile diabetes.
HUMULIN R may also be of value during preparation of a diabetic
patient for
surgery or for hyperglycemic coma, trauma, or severe infection.
DOSAGE AND ADMINISTRATION
The dosage should be determined by the physician, according to the
requirements
of the patient.
All HUMULIN preparations may be given by subcutaneous or intramuscular
injection, but HUMULIN R may also